Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases

BackgroundToll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors i...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer Vol. 12; no. 7; p. e008837
Main Authors: Ghosh, Chandra C, Cournoyer, Lauren, Liu, Yujia, Ballarin, Alizee, Layman, Ilan B, LaPorte, Jason, Morrissey, Molly, Fraser, Kayla, Perati, Shriya, Cox, Bryan F, Yakirevich, Evgeny, Treaba, Diana O, Murtha, Timothy D, Guha, Prajna, Katz, Steven C, Davar, Diwakar
Format: Journal Article
Language:English
Published: England BMJ Publishing Group Ltd 22.07.2024
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects:
ISSN:2051-1426, 2051-1426
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first